NC-LENOVO
25.2.2021 15:02:09 CET | Business Wire | Press release
The world’s greatest adventure and action sports imagery contest, Red Bull Illume® returns in 2021 with global technology leader, Lenovo™, as its Exclusive Computing Sponsor. A showcase for the best of adventure and action sports imagery, the competition is expected once again to receive tens of thousands of entries from around the world including some of the most creative and extreme images ever captured. As part of this two-year partnership, Lenovo will be involved through brand, product placement and logo incorporation for both online and in-person content, prizes for finalists and winners, as well as having promotional access to the incredible contest imagery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005071/en/
Lenovo enables a more inclusive and inspired world for all through smarter technology, so it’s fitting Lenovo should present this year’s Best of Instagram category that opens up the competition to all. Unlike the contest’s nine other categories which are adjudicated by a panel of 50 photo and digital experts from around the world, the finalists and category winners for Best of Instagram by Lenovo are selected through public voting. Each month, from March 1 to July 31, 2021, there will be five still and five moving images pre-selected by an internal jury which are put out to a community vote. The top choices from each month will become official Red Bull Illume Image Quest 2021 Finalists; from these, a final online vote will decide the best still image and the best moving image, to be crowned as Lenovo’s Best of Instagram Category Winners. Anyone can submit their moving or still images on Instagram by tagging @redbullillume and #rbi21submission .
The Overall Winner of Red Bull Illume Image Quest 2021 is selected from all the category winners by the international judging panel. There is a total of 10 categories which are created to truly shine a light on the lifestyle and culture behind today’s professional and amateur content creators and their dedication to the craft. Each edition of the contest brings out a new level of never-seen-before creativity, and this edition is bound to be full of imagery that pushes the boundaries of content creation in adventure and action sports imagery.
Along with receiving well-earned career exposure as an official Red Bull Illume winner, their work will tour the globe, illuminated on huge lightboxes. The winners are also awarded prize packages that include trophies and the latest Lenovo products to power even more creative self-expression. Their work will be included in the official Red Bull Illume photobook and showcased during the winner award ceremony planned for November 2021 and attended by Ulrich Grill, the founder of the Red Bull Illume Image Quest.
“Lenovo is proud to support the sixth edition of Red Bull Illume Image Quest that brings together photographers and content creators whose bold work continually inspires us,” said Matt Bereda, Vice President of Global Consumer Marketing, PCs and Smart Devices, Lenovo . “We see many of our consumer PC, smart home, and tablet customers are passionate hobbyists. They enjoy photography and digital storytelling, and not all of them are paid professionals—they just love capturing and enhancing imagery to share with others and hang on their walls. If this new normal has taught us anything about our world and ourselves, it’s that we’re resilient, our technology is adaptable, and that making meaningful connections with others through shared creative pursuits are the bright spots in life that really matter.”
“Red Bull Illume is like the Oscars of adventure and action sports imagery and we are extremely proud to have Lenovo join the 2021 edition,” said Ulrich Grill, Founder of Red Bull Illume . “This contest honors the creativity and hard work that goes into producing one-of-a-kind imagery and Lenovo gives content creators the tools they need to express their unique ideas.”
A shared dedication to transformative experiences and using innovative technology to push boundaries makes Red Bull Illume and Lenovo ideal partners. Meaningful innovation is essential to advancing photo technologies and solidifying image capture as an artform. Similarly, Lenovo innovation provides digital creators with better photo management and enhancement experiences and smarter technology so they can build bigger for a more creative world – making consumer products, services, and software solutions more attuned to the unique needs of modern content creators.
The contest is open for submissions from March 1 to July 31, 2021. It is free for anyone to enter and voting is open to all on redbullillume.com . To view previous winning images, check out the gallery, here .
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$50 billion Fortune Global 500 company, with 63,000 employees and operating in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that create a more inclusive, trustworthy and sustainable digital society. By designing, engineering and building the world’s most complete portfolio of smart devices and infrastructure, we are also leading an Intelligent Transformation – to create better experiences and opportunities for millions of customers around the world. To find out more visit https://www.lenovo.com , follow us on LinkedIn , Facebook , Twitter , YouTube , Instagram , Weibo and read about the latest news via our StoryHub .
About Red Bull Illume
The Image Quest 2021 is the sixth edition bringing together the amazing work of photographers and content creators from around the world. In 2019, a record-breaking 59,551 images were submitted by thousands of creators from countries all around the world. Submissions for the contest will take place from March 1 to July 31, 2021 and can be entered on redbullillume.com and on Instagram. A judging panel of 50 photo editors and digital experts will select the Finalists, Category Winners and an Overall Winner, to be unveiled at the Winner Award Ceremony in November 2021. Follow us on Instagram, Facebook, Twitter, YouTube and Pinterest.
LENOVO is a trademark of Lenovo. RED BULL ILLUME is a trademark of Red Bull GmbH. Instagram is a trademark of Instagram, LLC. All other trademarks are the property of their respective owners. ©2021, Lenovo Group Limited.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005071/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom